Panel Biotech Startup Showcase Stage 2 track
Scaling Up: Strategies for Closing Your Series A Round
Mon, Nov 16, 2026 · 12:30–1:00 PM GMT Old Billingsgate
About this session
The Series A represents a critical inflection point where biotech companies must demonstrate meaningful progress beyond seed-stage promise. With larger check sizes and higher expectations, VCs are looking for validated biology, clear clinical or commercial pathways, and teams capable of scaling. This panel features Series A investors who will discuss what separates fundable companies from those that stall, how to position your data package for maximum impact, and what valuation and dilution dynamics founders should expect.
